{{Rsnum
|rsid=2231137
|Gene=ABCG2
|Chromosome=4
|position=88139962
|Orientation=minus
|ReferenceAllele=G
|MissenseAllele=A
|GMAF=0.1405
|Gene_s=ABCG2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 3.1 | 96.9
| HCB | 0.0 | 57.8 | 42.2
| JPT | 4.5 | 29.5 | 65.9
| YRI | 0.0 | 9.5 | 90.5
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 57.8 | 42.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}
[[rs2231137]], also known as Val12Met, is a SNP in the ATP-binding cassette, sub-family G (WHITE), member 2 [[ABCG2]] gene. The (G) allele encodes the Val.

In a study of incident ischemic [[stroke]] during 14 years of follow-up in a population-based study of older adults known as the Cardiovascular Health Study (CHS), [[rs2231137]] was associated with stroke in both white (hazard ratio, 1.46, CI: 1.05 - 2.03) and black (hazard ratio, 3.59, CI, 1.11 - 11.6) participants. The risk of ischemic stroke was higher in Val allele homozygotes than in Met allele carriers. The adjusted hazard ratio for Val allele homozygotes, compared with Met allele carriers, was 1.50 (90% CI, 1.06 to 2.12) in whites and 3.62 (90% CI, 1.11 to 11.9) in black participants (Table 4). {{PMID|19023099|OA=1
}}

{{PharmGKB
|RSID=rs2231137
|Name_s=ABCG2:V12M
|Gene_s=ABCG2
|Feature=Exon/NonSyn
|Evidence=PubMed ID:17509035
|Annotation=control size=7; M12 cases=6; PK=in healthy subjects, disposition of lamivudine was not significantly influenced by known functional variants
|Drugs=lamivudine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165109683
}}

{{PMID Auto
|PMID=21311724
|Title=Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia
|OA=1
}}

{{PMID Auto
|PMID=18547414
|Title=Genotyping panel for assessing response to cancer chemotherapy.
|OA=1
}}

{{PMID Auto
|PMID=19584153
|Title=Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
}}

{{PMID Auto
|PMID=20389299
|Title=Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.
|OA=1
}}

{{GET Evidence
|gene=ABCG2
|aa_change=Val12Met
|aa_change_short=V12M
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2231137
|overall_frequency_n=483
|overall_frequency_d=10758
|overall_frequency=0.0448968
|n_genomes=7
|n_genomes_annotated=0
|n_haplomes=8
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|nblosum100=0
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}